Opiant Pharmaceuticals, Inc. (OPNT): Price and Financial Metrics

Opiant Pharmaceuticals, Inc. (OPNT): $20.17

-0.02 (-0.10%)

POWR Rating

Component Grades














  • Quality is the dimension where OPNT ranks best; there it ranks ahead of 52.23% of US stocks.
  • The strongest trend for OPNT is in Stability, which has been heading up over the past 179 days.
  • OPNT ranks lowest in Growth; there it ranks in the 3rd percentile.

OPNT Stock Summary

  • With a one year PEG ratio of 0.26, OPIANT PHARMACEUTICALS INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 3.14% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, OPIANT PHARMACEUTICALS INC is reporting a growth rate of -1,193.34%; that's higher than only 1.28% of US stocks.
  • Revenue growth over the past 12 months for OPIANT PHARMACEUTICALS INC comes in at -49.13%, a number that bests just 3.78% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to OPIANT PHARMACEUTICALS INC, a group of peers worth examining would be SPRO, ACAD, VYNE, PGEN, and CGNT.
  • OPNT's SEC filings can be seen here. And to visit OPIANT PHARMACEUTICALS INC's official web site, go to www.opiant.com.

OPNT Valuation Summary

  • In comparison to the median Healthcare stock, OPNT's price/earnings ratio is 113.36% lower, now standing at -3.1.
  • OPNT's price/sales ratio has moved NA NA over the prior 155 months.

Below are key valuation metrics over time for OPNT.

Stock Date P/S P/B P/E EV/EBIT
OPNT 2022-11-25 4.6 5.1 -3.1 -2.7
OPNT 2022-11-23 4.6 5.1 -3.1 -2.7
OPNT 2022-11-22 4.6 5.1 -3.1 -2.7
OPNT 2022-11-21 4.6 5.1 -3.1 -2.7
OPNT 2022-11-18 4.6 5.1 -3.1 -2.7
OPNT 2022-11-17 4.7 5.1 -3.1 -2.7

OPNT Growth Metrics

    Its 3 year cash and equivalents growth rate is now at 103.32%.
  • The 5 year price growth rate now stands at 56.25%.
  • Its 2 year revenue growth rate is now at 16.51%.
OPNT's revenue has moved down $18,181,419 over the prior 33 months.

The table below shows OPNT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 22.33838 -15.46532 -33.08868
2022-06-30 38.50357 -10.43864 -19.75495
2022-03-31 45.8686 -1.889263 -6.33481
2021-12-31 47.78548 1.926489 3.00879
2021-09-30 43.90924 -1.710752 1.570885
2021-06-30 36.67626 -1.575582 -1.12124

OPNT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OPNT has a Quality Grade of C, ranking ahead of 70.58% of graded US stocks.
  • OPNT's asset turnover comes in at 0.656 -- ranking 5th of 42 Non-Metallic and Industrial Metal Mining stocks.
  • MLM, USAU, and USLM are the stocks whose asset turnover ratios are most correlated with OPNT.

The table below shows OPNT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.656 1 -0.014
2021-03-31 0.631 1 -0.160
2020-12-31 0.656 1 -0.237
2020-09-30 0.683 1 -0.048
2020-06-30 0.977 1 1.887
2020-03-31 1.059 1 3.677

OPNT Price Target

For more insight on analysts targets of OPNT, see our OPNT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $41.33 Average Broker Recommendation 1.5 (Moderate Buy)

OPNT Stock Price Chart Interactive Chart >

Price chart for OPNT

OPNT Price/Volume Stats

Current price $20.17 52-week high $37.71
Prev. close $20.19 52-week low $7.34
Day low $20.12 Volume 33,800
Day high $20.23 Avg. volume 63,990
50-day MA $12.89 Dividend yield N/A
200-day MA $15.28 Market Cap 104.16M

Opiant Pharmaceuticals, Inc. (OPNT) Company Bio

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops opioid antagonist treatments for addictions and related disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. It is also involved in developing treatments for binge eating disorder and cocaine use disorder, as well as Bulimia Nervosa, an eating disorder; and heroin vaccine. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is based in Santa Monica, California. Opiant Pharmaceuticals, Inc. operates as a subsidiary of Pelikin Group.

OPNT Latest News Stream

Event/Time News Detail
Loading, please wait...

OPNT Latest Social Stream

Loading social stream, please wait...

View Full OPNT Social Stream

Latest OPNT News From Around the Web

Below are the latest news stories about OPIANT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate OPNT as an investment opportunity.

Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose

SANTA MONICA, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced it has completed submission of its rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for OPNT003, nasal nalmefene, for the treatment of opioid overdose. “We are very pleased to submit our NDA for OPNT003,” said Roger Crystal, M.D., President and Chief Executive Officer of Opiant. “We believe the data supporting this NDA in

Yahoo | November 22, 2022

How Will Indivior’s $145M Purchase of Opiant Boost the Stock?

UK-based Indivior PLC (OTCMKTS:INVVY) (GB:INDV) has offered to buy U.S.-based Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) for roughly $145 million. Indivior has proposed to pay upfront $20 per share for each outstanding share of Opiant. Also, Indivior will pay an additional $8 per share to Opiant over a period of seven years, if the latter is able to gain approval and revenue thresholds for a potential overdose reversal medication. The upfront offer price represents a 111% premium to Opiant’s closing price of November 11 and a 195% premium including the contingent value rights (CVRs) payment of $8 per share. The acquisition is approved by the boards of both companies.

Sheryl Sheth on TipRanks | November 14, 2022

Stocks Cool Off From Last Week's Rally

Stocks are starting the week off lower, unable to build off of last week's impressive rally.

TalkMarkets.com | November 14, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back and get ready for the week with a breakdown of the biggest pre-market stock movers worth knowing about on Monday morning!

William White on InvestorPlace | November 14, 2022

Party City Layoffs 2022: What to Know About the PRTY Job Cuts

Party City (PRTY) is the latest company to announce layoffs as it prepares to cut 19% of its workforce due to rising inflation.

William White on InvestorPlace | November 14, 2022

Read More 'OPNT' Stories Here

OPNT Price Returns

1-mo 104.05%
3-mo 77.87%
6-mo 56.36%
1-year -38.45%
3-year 46.58%
5-year -35.68%
YTD -40.02%
2021 318.80%
2020 -44.24%
2019 -0.35%
2018 -37.09%
2017 309.45%

Continue Researching OPNT

Here are a few links from around the web to help you further your research on Opiant Pharmaceuticals Inc's stock as an investment opportunity:

Opiant Pharmaceuticals Inc (OPNT) Stock Price | Nasdaq
Opiant Pharmaceuticals Inc (OPNT) Stock Quote, History and News - Yahoo Finance
Opiant Pharmaceuticals Inc (OPNT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7744 seconds.